Excited to share the latests results from the STAMPEDE clinical trial: abiraterone plus prednisolone with or without enza added to ADT compared to ADT alone in high risk nonmetastatic #prostatecancer patients #ESMO21 
None of this would be possible without all the patients, supported by their family/friends, all the site staff involved in the trial, our pharma partners @AstellasEurope @JanssenUK, our funders @The_MRC @CR_UK, and the efforts of the whole team @MRCCTU #ESMO21
More details on the study design enabling this comaprison, including our amendment to the reporting plan reader.elsevier.com/reader/sd/pii/… #ESMO21
2 years of abiraterone+prednisolone based therapy significantly improves metastasis-free survival and overall survival of high risk nonmetastatic prostate cancer patients and should be considered a new standard of care #ESMO21
Looking forward to the discussion session #ESMO21
Read more on @CR_UK blog news.cancerresearchuk.org/2021/09/19/com…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
